5 hours ago
1
CR/iStock via Getty Images
Novo Nordisk (NVO) has been upgraded to Outperform from Market Perform at Bernstein, citing the growth potential within the company's obesity franchise.
Analysts at Bernstein said that the upgrade is supported by Novo’s performance in the obesity drug market, where products
English (US) ·